Arjo (OM:ARJO B) Stock Faces Margin Pressure As Net Profit Trails Bullish Narrative

Arjo (OM:ARJO B) has reported Q2 2026 revenue of SEK2.8b and basic EPS of SEK0.46, with net income excluding extra items at SEK125m setting the tone for this earnings season update. The company has seen quarterly revenue move from SEK2.7b in Q1 2026 to SEK2.8b in Q2 2026, while basic EPS has shifted from SEK0.40 to SEK0.46 over the same period, giving investors a clearer view of how the top and bottom line are tracking into mid 2026. With trailing net margin at 3.5% and slightly lower than last year’s 3.8%, the focus this quarter is on how much of that revenue Arjo can keep as profit.

See our full analysis for Arjo.

With the headline numbers set, the next step is to see how this latest report compares with the widely followed narratives on Arjo’s growth potential, risks, and profitability trajectory.

See what the community is saying about Arjo

Net income at SEK125m tests bullish profit story

• Q2 2026 net income excluding extra items sits at SEK125m, compared with SEK108m in Q1 2026 and SEK92m in Q2 2025. The trailing twelve month figure is SEK384m on SEK10.9b of revenue, which lines up with a 3.5% net margin versus 3.8% a year earlier.
• Bulls argue that cost efficiency efforts and structural healthcare demand can lift Arjo’s margins over time, yet
  • the 3.5% trailing margin versus 3.8% a year earlier shows that margin pressure is still present even as quarterly net income has moved from SEK70m in Q4 2025 to SEK125m in Q2 2026.
  • the bullish view of margin expansion sits against five year earnings that declined 12.8% per year, so the recent profit level needs to be seen in the context of a weaker longer term earnings track record.

For readers who think the latest profit trend could support the optimistic case, it is worth seeing how Arjo bulls frame the long term earnings path through the 🐂 Arjo Bull Case.

DCF fair value of SEK64.44 vs SEK27.06 price

• The shares trade at SEK27.06, compared with a DCF fair value of SEK64.44 and a P/E of 19.2x, which is below both peers at 33.1x and the European Medical Equipment industry at 26.7x. Revenue growth of 3.8% per year is set against the Swedish market’s forecast of a 0.08% annual decline.
• Consensus narrative points to Arjo as “good value” relative to peers, and the current numbers highlight both support and checks on that story, as
  • the large gap between the SEK27.06 share price and the SEK64.44 DCF fair value supports the idea that the stock is priced cautiously despite forecast earnings growth of about 20% per year.
  • the same dataset flags high debt and an unstable dividend record alongside a 3.5% net margin, which reminds investors that the low P/E and discount to DCF fair value come with balance sheet and income reliability considerations.

3.8% revenue growth vs softer multi year earnings

• Over the last 12 months Arjo’s revenue growth rate of 3.8% per year sits alongside trailing twelve month EPS of SEK1.41, compared with SEK1.68 a year earlier, and trailing net income of SEK384m versus SEK457m in the prior year period. This indicates that the business generated more modest earnings on a slightly lower revenue base than a year ago.
• Bears highlight that five year earnings declined 12.8% per year and see the 3.5% current net margin as vulnerable, and the figures here both support and limit that concern, since
  • the step from quarterly EPS of SEK0.26 in Q4 2025 to SEK0.46 in Q2 2026 suggests profits have been recovering recently even though the trailing EPS remains below last year’s SEK1.68.
  • revenue at SEK2,759m in Q2 2026 is close to SEK2,678m in Q2 2025, so bears focused on structural pressure may note that revenue growth has been modest while earnings over several years have declined, which fits their caution on long term profitability.

Skeptics who see the softer multi year earnings trend as the key issue may want to compare these figures with how the cautious view on Arjo frames margin and cash flow risk in the 🐻 Arjo Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Arjo on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With opinions on Arjo pulling in both directions, consider taking a closer look at the numbers yourself and forming a view before sentiment shifts. To see a concise breakdown of the main concerns and potential upsides, start with these 3 key rewards and 2 important warning signs.

See What Else Is Out There

Arjo’s modest 3.5% net margin, softer multi year earnings and flagged balance sheet concerns suggest profits and financial resilience are not yet where many investors might want them.

If you want companies where financial strength is more of a feature than a question mark, check out the solid balance sheet and fundamentals stocks screener (419 results) to quickly focus on sturdier options.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com